WE'VE GOT YOU COVERED
GET A $0 CO-PAY*
If you have commercial insurance, we'll help you get your medication as quickly as possible. You'll have no co-pay to worry about if you're eligible for our $0 co-pay program.
*Limitations apply. For those commercially insured and 18 years or older. Up to a $16,000 annual cap. You will be responsible for any co-pay once limit is reached in a calendar year. This offer is not valid under Medicare, Medicaid, or any other federal or state program. Not valid for cash-paying patients. Novartis reserves the right to rescind, revoke, or amend this program without notice. Enrollment expires 12/31/18.
If you have commercial insurance, we'll help you get your medication as quickly as possible. If your coverage is denied, you may get up to 2 years of COSENTYX for free while we work with your insurance company to set up your coverage.†
Covered Until You're Covered Program: Eligible patients must have commercial insurance, a valid prescription for COSENTYX, and a denial of insurance coverage based on a prior authorization request. Program requires the submission of an appeal of the coverage denial within the first 90 days of enrollment in order to remain eligible. Program provides initial 5 weekly doses (if prescribed) and monthly doses for free to patients for up to two years or until they receive insurance coverage approval, whichever occurs earlier. Program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, Tricare, or any other federal or state program. Patients may be asked to re-verify insurance coverage status during the course of the program. No purchase necessary. Program is not health insurance, nor is participation a guarantee of insurance coverage. Limitations may apply. Enrolled patients awaiting coverage for COSENTYX after two years may be eligible for a limited Program extension. Novartis Pharmaceuticals Corporation reserves the right to rescind, revoke, or amend this Program without notice. Program enrollment must occur by 12/31/18.